ImmunogenicityAllergenic Activity and Preserve Grass Pollen Allergen, Phl p 6, to Reduce Genetic Engineering of the Major Timothy
暂无分享,去创建一个
A. Fedorov | S. Almo | R. Valenta | P. Valent | W. Sperr | W. Keller | J. Kopeć | P. Verdino | A. Hartl | J. Thalhamer | S. Vrtala | M. Focke | T. Ball
[1] R. Esch. Grass pollen allergens. , 2020, Clinical allergy and immunology.
[2] Matthew Plante,et al. Reduced Allergenic Potency of VR9-1, a Mutant of the Major Shrimp Allergen Pen a 1 (Tropomyosin)1 , 2005, The Journal of Immunology.
[3] R. Coffman,et al. Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction , 2005, The Journal of experimental medicine.
[4] M. Jutel,et al. Allergen-specific immunotherapy with recombinant grass pollen allergens. , 2005, The Journal of allergy and clinical immunology.
[5] C. Akdis,et al. Cytokine and Antibody Responses in Birch-Pollen-Allergic Patients Treated with Genetically Modified Derivatives of the Major Birch Pollen Allergen Bet v 1 , 2005, International Archives of Allergy and Immunology.
[6] Franz König,et al. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. , 2005, The Journal of allergy and clinical immunology.
[7] R. Valenta,et al. A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. , 2005, The Journal of allergy and clinical immunology.
[8] D. Wraith,et al. Peptide-based therapeutic vaccines for allergic and autoimmune diseases , 2005, Nature Medicine.
[9] S. Ying,et al. Fel d 1‐derived T cell peptide therapy induces recruitment of CD4+CD25+; CD4+ interferon‐γ+ T helper type 1 cells to sites of allergen‐induced late‐phase skin reactions in cat‐allergic subjects , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[10] E. Vartiainen,et al. IgE Reactivity Pattern to Timothy and Birch Pollen Allergens in Finnish and Russian Karelia , 2005, International Archives of Allergy and Immunology.
[11] P. Bhalla,et al. Engineered allergens for immunotherapy , 2004, Current opinion in allergy and clinical immunology.
[12] K Henrick,et al. Electronic Reprint Biological Crystallography Secondary-structure Matching (ssm), a New Tool for Fast Protein Structure Alignment in Three Dimensions Biological Crystallography Secondary-structure Matching (ssm), a New Tool for Fast Protein Structure Alignment in Three Dimensions , 2022 .
[13] H. Grönlund,et al. Vaccination with genetically engineered allergens prevents progression of allergic disease , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[14] R. Valenta,et al. Vaccine Engineering Improved by Hybrid Technology , 2004, International Archives of Allergy and Immunology.
[15] Lee Whitmore,et al. DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data , 2004, Nucleic Acids Res..
[16] R. Valenta,et al. Generation of an Allergy Vaccine by Disruption of the Three-Dimensional Structure of the Cross-Reactive Calcium-Binding Allergen, Phl p 71 , 2004, The Journal of Immunology.
[17] R. Valenta,et al. Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1 , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[18] R. Valenta,et al. Analysis of the sensitization profile towards allergens in central Africa , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[19] P. Colombo. Hypoallergenic variants of the Parietaria judaica major allergen Par j 1: in vitro and in vivo evaluation. , 2003, Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M.
[20] R. Valenta,et al. The FASEB Journal express article 10.1096/fj.01-1012fje. Published online June 21, 2002. , 2022 .
[21] R. Valenta. The future of antigen-specific immunotherapy of allergy , 2002, Nature Reviews Immunology.
[22] M. Wills-Karp,et al. Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. , 2002, The Journal of allergy and clinical immunology.
[23] Erkka Valovirta,et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). , 2002, The Journal of allergy and clinical immunology.
[24] Lee Whitmore,et al. DICHROWEB: an interactive website for the analysis of protein secondary structure from circular dichroism spectra , 2002, Bioinform..
[25] S. Monasterolo,et al. Measurement of IgE antibodies against purified grass‐pollen allergens (Phl p 1, 2, 3, 4, 5, 6, 7, 11, and 12) in sera of patients allergic to grass pollen , 2001, Allergy.
[26] R. Valenta,et al. Skin test results but not serology reflect immediate type respiratory sensitivity: a study performed with recombinant allergen molecules. , 2001, The Journal of investigative dermatology.
[27] R. Valenta,et al. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[28] P. Hufnagl,et al. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1 , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[29] A. Kagey‐Sobotka,et al. Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy. , 2001, The Journal of allergy and clinical immunology.
[30] F. Horak,et al. A well‐tolerated grass pollen‐specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections , 2001, Allergy.
[31] R. Valenta,et al. Recombinant allergen molecules: tools to study effector cell activation , 2001, Immunological reviews.
[32] C. Suphioglu. What are the important allergens in grass pollen that are linked to human allergic disease? , 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[33] B. Haselden,et al. Peptide-Mediated Immune Responses in Specific Immunotherapy , 2000, International Archives of Allergy and Immunology.
[34] E. Raz,et al. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. , 2000, The Journal of allergy and clinical immunology.
[35] M. Nadler,et al. Signal transduction by the high-affinity immunoglobulin E receptor Fc epsilon RI: coupling form to function. , 2000, Advances in immunology.
[36] J. Kinet,et al. Signalling through the high-affinity IgE receptor FcεRI , 1999, Nature.
[37] R. Valenta,et al. Molecular, immunological, and structural characterization of Phl p 6, a major allergen and P-particle-associated protein from Timothy grass (Phleum pratense) pollen. , 1999, Journal of immunology.
[38] R. Valenta,et al. Component-resolved diagnosis (CRD) of type I allergy with recombinant grass and tree pollen allergens by skin testing. , 1999, The Journal of investigative dermatology.
[39] P. Bhalla,et al. Genetically Engineered Plant Allergens with Reduced Anaphylactic Activity , 1999, International Archives of Allergy and Immunology.
[40] M. Schlaak,et al. "Allergen engineering": variants of the timothy grass pollen allergen Phl p 5b with reduced IgE-binding capacity but conserved T cell reactivity. , 1999, Journal of immunology.
[41] J. Kinet,et al. Signalling through the high-affinity IgE receptor Fc epsilonRI. , 1999, Nature.
[42] Giorgio Walter Canonica,et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases , 1998 .
[43] J Bousquet,et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. , 1998, The Journal of allergy and clinical immunology.
[44] R. Valenta,et al. Immunization with purified natural and recombinant allergens induces mouse IgG1 antibodies that recognize similar epitopes as human IgE and inhibit the human IgE-allergen interaction and allergen-induced basophil degranulation. , 1998, Journal of immunology.
[45] C. Akdis,et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. , 1998, The Journal of allergy and clinical immunology.
[46] R. Valenta,et al. IgE antibodies to recombinant pollen allergens (Phl p 1, Phl p 2, Phl p 5, and Bet v 2) account for a high percentage of grass pollen-specific IgE. , 1998, The Journal of allergy and clinical immunology.
[47] R. Valenta,et al. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. , 1997, The Journal of clinical investigation.
[48] R. Valenta,et al. Induction of IgE antibodies in mice and rhesus monkeys with recombinant birch pollen allergens: different allergenicity of Bet v 1 and Bet v 2. , 1996, The Journal of allergy and clinical immunology.
[49] R. Valenta,et al. Comparison of recombinant timothy grass pollen allergens with natural extract for diagnosis of grass pollen allergy in different populations. , 1996, The Journal of allergy and clinical immunology.
[50] C. Dolecek,et al. Immunologic characterization of purified recombinant timothy grass pollen (Phleum pratense) allergens (Phl p 1, Phl p2, Phl p 5). , 1996, The Journal of allergy and clinical immunology.
[51] J. Hughes,et al. Genetically engineered vaccines. , 1995, American pharmacy.
[52] M. Schlaak,et al. Characterization of the allergen group VI in timothy grass pollen (Phl p 6). II. cDNA cloning of Phl p 6 and structural comparison to grass group V. , 1995, International archives of allergy and immunology.
[53] N L Harris,et al. Four helix bundle diversity in globular proteins. , 1994, Journal of molecular biology.
[54] M. Muhm,et al. Interleukin 3 activates human blood basophils via high-affinity binding sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[55] S. Fling,et al. Peptide and protein molecular weight determination by electrophoresis using a high-molarity tris buffer system without urea. , 1986, Analytical biochemistry.
[56] H. Towbin,et al. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[57] K. Mathews. Immunotherapy for allergic disease. , 1976, Comprehensive therapy.
[58] K. Ishizaka,et al. Physicochemical properties of reaginic antibody. V. Correlation of reaginic activity wth gamma-E-globulin antibody. , 1966, Journal of immunology.